Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia

References

• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Lazarevic V, Horstedt AS, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119:3890–3899.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Reinhardt D, et al. Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer. 2016;122:3821–3830.
   PubMed Web of Science ®Google Scholar
• Heiblig M, Elhamri M, Le Jeune C, et al. Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors. Eur J Haematol. 2017;98:134–141.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Tooze JA, Pardee TS, et al. Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia. J Am Geriatr Soc. 2016;64:1988–1995.
   PubMed Web of Science ®Google Scholar
• Wass M, Hitz F, Schaffrath J, et al. Value of different comorbidity indices for predicting outcome in patients with acute myeloid leukemia. PLoS One. 2016;11:e0164587.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569–3576.
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916–1924.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang T, Zheng X, et al. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy. Medicine. 2016;95:e4182.
   PubMed Web of Science ®Google Scholar
• Carella AM, Cascavilla N, Greco MM, et al. Treatment of “poor risk” acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study. Leuk Lymph. 2001;40:295–303.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee JH, Joo YD, et al. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients’ trial. Eur J Haematol. 2016;96:188–197.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116:4422–4429.
   PubMed Web of Science ®Google Scholar
• Boddu PC, Kantarjian HM, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer. 2017;123:3050–3060.
   PubMed Web of Science ®Google Scholar
• Lam SS, He AB, Leung AY. Treatment of acute myeloid leukemia in the next decade - towards real-time functional testing and personalized medicine. Blood Rev. 2017;31:418–425.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97:393–401.
   PubMed Web of Science ®Google Scholar
• Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6:6448–6458.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32:2541–2552.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606–4613.
   PubMed Web of Science ®Google Scholar
• Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98:208–216.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhu H, Wu W, et al. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia. Leuk Lymph. 2014;55:371–377.
   PubMed Web of Science ®Google Scholar
• Qiao C, Zhang R, Hong M, et al. Heterogeneous leukemic clones identified by NPM1 mutation analysis in patient with acute monocytic leukemia. Leuk Lymph.2012;53:886–890.
   PubMed Web of Science ®Google Scholar
• Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376:2000–2008.
   PubMed Web of Science ®Google Scholar
• Kim DS, Kang KW, Yu ES, et al. Selection of elderly acute myeloid leukemia patients for intensive chemotherapy: effectiveness of intensive chemotherapy and subgroup analysis. Acta Haematol. 2015;133:300–309.
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol. 2013;31:3110–3118.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120:4840–4845.
   PubMed Web of Science ®Google Scholar
• Klco JM, Spencer DH, Lamprecht TL, et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 2013;121:1633–1643.
   PubMed Web of Science ®Google Scholar
• Kurimoto M, Matsuoka H, Hanaoka N, et al. Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia. 2013;27:233–235.
   PubMed Web of Science ®Google Scholar
• Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011;118:1472–1480.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254–266.
   PubMed Web of Science ®Google Scholar
• Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007;13:4225–4232.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhao H, Zhang X, et al. Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen-mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia. Biol Blood Marrow Transplant. 2017;23:830–835.
   PubMed Web of Science ®Google Scholar
• Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121:4287–4294.
   PubMed Web of Science ®Google Scholar
• Wang J, Yi Z, Wang S, et al. The effect of decitabine on megakaryocyte maturation and platelet release. Thromb Haemost. 2011;106:337–343.
   PubMed Web of Science ®Google Scholar